All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract: Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
By Claire Baker
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Jesus D. Gonzalez-Lugo, Montefiore Medical Center, presented the results from a phase II study evaluating the combination of eltrombopag and lenalidomide for the treatment of patients with symptomatic anemia and low- or intermediate-risk myelodysplastic syndrome. The MDS Hub is pleased to present a visual abstract summarizing the key safety and efficacy data from this study.
Visual abstract
- Gonzalez-Lugo JD, et al. Oral abstract #65. ASH 2021; Dec 11, 2021; Atlanta, US. (NCT01772420)
More about...
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox